Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides

Volume: 5, Issue: 4, Pages: 427 - 433
Published: Apr 1, 2013
Abstract
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of lymphoid neoplasms. The incidence of CTCLs has risen over the last three decades. The most common CTCLs are mycosis fungoides and Sèzary syndrome. Therapies for CTCLs are various and range from skin-directed therapy to chemotherapy. Retinoids have been used in CTCL treatment since the 1980s with good results. Bexarotene is the first retinoid approved by the US FDA for CTCL therapy....
Paper Details
Title
Role of bexarotene in the treatment of cutaneous T-cell lymphoma: the clinical and immunological sides
Published Date
Apr 1, 2013
Volume
5
Issue
4
Pages
427 - 433
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.